BioPharmX Corporation BPMX
Last Post: 05/14/2020 4:49:35 PM
Board Marks: 10
Posts Today: 0
Board Views Today: 18
http://www.biopharmx.com/
BioPharmX, Inc. provides innovative healthcare products through its unique, patented platform technologies for pharmaceutical, over-the-counter (OTC), and supplement applications.
BioPharmX products address unmet needs in large, well-defined and under-served global markets including:
Dermatology
Aesthetics
Women’s health
Ear, nose and throat (ENT) therapy
At BioPharmX, we aim to touch lives by providing relief and restoring well-being.
By design, BioPharmX's innovative drug delivery products, with their unique patented platform technologies, are formulated to address the needs of well-defined, fast-growing, multi-billion dollar markets, including dermatology, aesthetics, otolaryngology (ears, nose & throat), and women’s health.
BioPharmX currently has multiple products in various stages of development in all three of these markets, but its first commercialized product will be a woman’s breast health product launching in January 2015.
BioPharmX creates unique drug delivery products for IP licensing or direct commercialization for pharmaceutical, over-the-counter, and supplement distribution and sales.
Our unique health and wellness products (for licensing and commercialization in pharmaceutical and over-the-counter (OTC) use) leverage our extensive experience in pharmacological and biological sciences and drug delivery product development. Our team is experienced in performing pre-clinical studies focused on analytics, pharmacokinetics and toxicology, experimental design, and investigational protocols. We do this through product research and development and through strategic partnerships with leading worldwide pharmaceutical companies.
Our commitment to providing customers with products that improve the quality of their lives can only be met through unrivaled innovation and a dedication to quality—both of which are integral parts of BioPharmX's company culture.
With significant investments in R&D and a deep background in pharmaceutical and medical device development, BioPharmX is uniquely positioned to bring leading-edge, over-the-counter (OTC) products to the retail marketplace. Our products all meet rigorous internal quality measurements and leverage the capabilities required for pharmaceutical grade FDA products.
BioPharmX enables innovative solutions by working with pharmaceutical companies worldwide to achieve shorter time-to-market scenarios. We do this through a suite of core competencies unique to our teams:
Customized solutions to fit drug formulation needs
Expertise in regulatory, toxicology and clinical studies
Streamlined pathways through development
Unrivaled commitment to quality
Our R&D team specializes in developing world-class clinical studies. They perform formulation development, outline safety profiles and dosing requirements, and set validation protocols. Currently they are developing a portfolio of patented drug applications (including novel formulations and minimally invasive delivery devices in respective markets) to be out-licensed or commercialized.
BioPharmX currently has multiple products in various stages of development for therapeutic drug delivery in the areas of women's health, dermatology, aesthetics and ENT.
BioPharmX partners with leading pharmaceutical companies through regulatory approval or performs all activities internally, utilizing our team of regulatory and product development experts. Our partners turn to us to enhance delivery characteristics to improve drug performance and patient compliance. Our proven methods and technologies provide our customers with unique and measurable technical and competitive advantages.
http://www.multivu.com/players/English/737895...iscomfort/
http://www.violetmd.com/#!learn-more/cofj
http://media.wix.com/ugd/a2ef15_3d6d63a38cdf4...52d973.pdf
One Med San Francisco 2014 Webcast http://www.onemedplace.com/onemedtv/play.php?vid=2570
Management Team
The BioPharmX management team consists of Silicon Valley executives, scientists and business professionals combining large company discipline with deep biotech expertise focused on drug delivery and molecular properties. The team has the proven ability to raise capital and streamline new technologies into viable, marketable and successful products.
Jim Pekarsky
CHIEF EXECUTIVE OFFICER
Mr. Pekarsky has devoted over 30 years to growing diverse medical research and high-tech companies, including Bio Rad Laboratories, Mentor Graphics, MoSys and Virage Logic. He has spent over 10 years as the Chief Financial Officer of several public and private companies and five years as a European General Manager for U.S. multinational corporations. For more than a decade he has been counseling start-ups in Silicon Valley and leading their financings, acquisitions and initial public offerings. Pekarsky holds an M.B.A. in finance from Golden Gate University in San Francisco and a bachelor’s degree in accounting from Indiana University of Pennsylvania.
Anja Krammer
PRESIDENT
A Silicon Valley veteran, Ms. Krammer has deep experience guiding healthcare and other enterprises to identify and fulfill unmet consumer needs. She has overseen marketing at diverse companies, such as aesthetic market leader Reliant Technologies, biomedical engineer Medtronic, print imaging manufacturer Tektronix and telecommunications giant AT&T. She has also counseled companies, such as American Express, GSK, Medicis Pharmaceuticals and Weight Watchers NA. Krammer graduated from the University of South Carolina and completed post-graduate studies at Webster University and the University of Paris – Sorbonne.
Kin F. Chan, Ph.D.
EXECUTIVE VICE PRESIDENT OF RESEARCH AND TECHNOLOGY
Dr. Chan is a serial biomedical entrepreneur who has developed novel, effective therapies for diverse medical conditions. His research and product development experience spans semiconductors, lasers/photonics, medical devices and biomedical sciences. He has therapeutic experience in dermatology, cardiology, urology and ophthalmology. Prior to BiopharmX, Chan was Vice President of Engineering at Demira, where he helped develop photodynamic therapies and directed advanced research at Solta Medical, where he helped create fractional photothermolysis technology. He is a co-inventor on more than 25 patents and pending patent applications. Chan holds a Ph.D. in electrical and computer engineering from the University of Texas at Austin, where he also achieved his bachelors and masters degrees.
Douglas Thomas, Ph.D.
CHIEF SCIENTIST
Dr. Thomas has more than 20 years of experience in biopharmaceutical research, process development, manufacturing and commercial development in start-ups and Fortune 500 companies. His background includes 10 years in business development and more than 10 years in research and development. He has consulted extensively in innovative start-ups focused on the application of diverse hardware and software in the biopharmaceutical industry. He has worked with a variety of biomedical companies, including BioSys Laboratories, Calypte Biomedical, Millipore and Invitrogen Life Technologies. Thomas holds a Ph.D. in immunology from Baylor College of Medicine and a bachelor’s degree in pharmacology from the University of California, Santa Barbara.
Jack Kessler, Ph.D.
SCIENTIFIC ADVISOR
Dr. Kessler has more than 35 years of applied development experience in the area of iodine-based formulations, bio-analytical assays, in vitro diagnostic (IVD) medical devices and regulatory affairs. He is a named inventor on more than 20 U.S. patents for analytical assays, IVD medical devices, iodine-based disinfectants and formulations and pharmaceutical dosage forms. Kessler has also authored more than 20 publications and book chapters and participated on six federal research grants from the National Institute of Health and the U.S. Department of Agriculture. He received a doctorate in biochemistry from SUNY at Syracuse and a bachelor’s degree in chemistry from Stevens Institute of Technology in New Jersey.
AnnaMarie Daniels
SENIOR VICE PRESIDENT OF REGULATORY AND CLINICAL AFFAIRS
Ms. Daniels is a microbiologist and biochemist by training and holds multiple patents. She has authored or contributed to dozens of peer reviewed articles and abstracts on subjects ranging from in vitro assays to breast cancer prevention. For the last 35 years she has held technical and executive level positions in start-up and development stage pharmaceutical and medical device companies working in the areas of implantable biomaterials, oncology, women’s health, pain, urology and interventional neuroradiology. She has been responsible for all aspects of company operations and has specific expertise in design and implementation of clinical and regulatory strategy for new product development. Prior to joining BioPharmX, she led the botulinum neurotoxin program at Johnson & Johnson, the clinical research program for Boston Scientific Neuromodulation and served as an independent consultant for a number of pharmaceutical and medical device companies.
Ross Portaro
SENIOR VICE PRESIDENT OF SALES
Mr. Portaro has 30 years of global sales executive experience in dermatology, women's health, and aesthetics. In dermatology, most recently as a sales director at Ulthera, he doubled sales and positioned them for their 2014 acquisition by Merz. At Medicis, Portaro led the LipoSonix team in Europe and facilitated the sale to Solta in 2011. In Women's Health, he built the original sales team at SenoRx, which was the leader in breast biopsies devices and had a successful 2007 IPO. In aesthetics, Mr. Portaro started TRIA Beauty as the Vice President of Sales and was the first medical laser executive to globally launch a medical-grade laser for hair removal into the consumer OTC Market. TRIA Beauty is positioned for a 2014 IPO. Mr. Portaro received his BS in Commerce from the McIntyre School of Commerce at the University of Virginia.
BioPharmX Corporation (OTCMRKTS: BPMX) Stock Message Board
Post
Subject
Author
Posted On
| 55 | RESEARCH REPORT UPDATE BPMX: A SPECIALTY PHARMA | Whos_Who | 10/08/2015 1:39:08 AM |
| 14 | Breast Health Medical Advisory Board Expertise | Whos_Who | 11/17/2014 10:07:31 AM |
| 12 | 10-Q Released | Whos_Who | 11/14/2014 9:46:39 PM |
| 11 | SEC Filings Released | Whos_Who | 11/12/2014 6:53:32 PM |
| 10 | BioPharmX Corporation Announces Appointment Of | Whos_Who | 11/10/2014 9:55:39 AM |
| 9 | BioPharmX Corporation Secures Up To $12 Million | Whos_Who | 11/10/2014 9:35:24 AM |
| 8 | BioPharmX supports Omnia Education and their | Whos_Who | 10/16/2014 9:36:43 PM |
| 7 | AAFP Assembly, Tuesday, October 21 - Saturday, | Whos_Who | 09/15/2014 1:15:36 PM |
| 5 | Jim Pekarsky, CEO of BioPharmx, a company based | Whos_Who | 09/12/2014 1:36:55 AM |
| 4 | BioPharmX website | Whos_Who | 09/12/2014 1:34:34 AM |
| 3 | Violet Iodine by BioPharmX. | Whos_Who | 09/12/2014 1:31:13 AM |
| 2 | BioPharmX currently has multiple products in | Whos_Who | 09/12/2014 1:25:21 AM |
| 1 | Welcome investors to BioPharmX | Whos_Who | 09/12/2014 1:22:27 AM |